Gilead Sciences delivered a better-than-expected second quarter, propelled by the strong performance of its HIV portfolio and ...

For anyone who wants to understand Gilead Sciences' profit beyond the statutory numbers, it's important to note that during ...

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look ...

Announced updated Phase 2 data at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, demonstrating deep and durable responses and a m ...

Aisera, a leading provider of agentic AI for business, and Apexon, a technology services firm specializing in engineering intelligent enterprises, today announced a strategic partnership. Together, ...

The Q2 pharma earnings season featured changes in the obesity race as well as insights into drugmakers’ views on tariffs and drug pricing.

Key Points Collaboration and license revenue (GAAP) for Q2 2025 was $8.1 million but missed Q2 2025 GAAP revenue estimates by $0.11 million. Net loss (GAAP) widened to $15.8 million, with increased ...

According to the latest study from BCC Research, "Global Markets for Infectious Disease Treatments" is expected to grow from ...

Royalty Pharma plc (Nasdaq: RPRX) today announced that Henry Fernandez, its Lead Independent Director, has stepped down from its Board of Directors, effective August 13, 2025. Mr. Fernandez joined the ...

Rising hopes of an interest-rate cut in September pushed US stocks higher on Wednesday, with the S&P 500 and Nasdaq both ...